Cafepharma Today

June 6 2025 - Novartis presses court for hasty decision in long-running Entresto patent feud with MSN
Novartis presses court for hasty decision in long-running Entresto patent feud with MSN
'Not a horse and pony show': At FDA cell and gene roundtable, officials look for ways to cut red tape
With ADCs on the rise, drugmakers embrace a new oncology pillar
Bayer trial combines two top drugs for kidney disease
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Forest Laboratories, Inc.: Feelings of Deja Vu?
Motley Fool
Sunday, February 2, 2014 - 11:37am
tags:
Namenda, Forest Labs, patent cliff, patents, generics
Fierce Competition in the Diabetes Drug Market
Motley Fool
Sunday, February 2, 2014 - 11:36am
tags:
diabetes, GSK, Sanofi, Astra Zeneca, Bristol-Myers Squibb, Novo Nordisk, Eli Lily, Takeda
3 Things to Watch in Merck's Upcoming Earnings
Motley Fool
Sunday, February 2, 2014 - 11:34am
tags:
Merck, earnings
The Case For Questcor
Seeking Alpha
Sunday, February 2, 2014 - 11:32am
tags:
Questcor Pharmaceuticals
Inovio Neglected The Sign: Don't Feed The Bears!
Seeking Alpha
Sunday, February 2, 2014 - 11:31am
tags:
Inovio
This Week in Biotech: Let's Get Clinical!
Motley Fool
Sunday, February 2, 2014 - 11:30am
tags:
AbbVie, Enanta Pharmaceuticals, ABT-450, hepatitis C, Medivation, Xtandi, prostate cancer, Astellas, Geron, imetelstat, PSMA-ADC, Progenics Pharmaceuticals, Idenix
A Unique Take On Pharmaceutical Research
Bioresearch Online
Saturday, February 1, 2014 - 11:14am
tags:
UCB Pharmaceuticals
Aerie Pharmaceuticals Initiates Phase 2b Study of PG324, a Novel Fixed-Combination Product to Treat Patients with Glaucoma or Ocular Hypertension
FierceBiotech
Saturday, February 1, 2014 - 11:12am
tags:
PG324, ocular hypertension, glaucoma, Aerie Pharma
Johnson & Johnson's 3 Fastest-Growing Businesses
Motley Fool
Saturday, February 1, 2014 - 11:09am
tags:
JNJ
Heart Attack Risk of Testosterone Drugs Under U.S. Review
Bloomberg
Saturday, February 1, 2014 - 10:54am
tags:
testosterone
Galena Biopharma: Numerous Red Flags Suggest A Significant Overvaluation
Seeking Alpha
Saturday, February 1, 2014 - 10:53am
tags:
Galena Biopharma
Amgen Goes 6 for 6 Fighting Cholesterol
Motley Fool
Saturday, February 1, 2014 - 10:52am
tags:
Amgen, cholesterol, hypercholesterolemia, evolocumab
CytRx Flushed Its Shareholders, Even If It Needed the Capital
24-7 Wallstreet
Saturday, February 1, 2014 - 10:51am
tags:
CytRx
AbbVie Headed to FDA, Clash With Gilead Set
Motley Fool
Saturday, February 1, 2014 - 10:49am
tags:
AbbVie, Gilead Sciences, ABT-450, hepatitis, hepatitis C, Enanta Pharmaceuticals
TetraLogic Pharmaceuticsls And The Chatter About A Cure For Cancer
Seeking Alpha
Saturday, February 1, 2014 - 10:47am
tags:
TetraLogic
This Biotech Winner Could Deliver 20% Profits by Mid-2014
Yahoo/Street Authority
Saturday, February 1, 2014 - 10:45am
tags:
Vertex Pharmaceuticals
Vanda Pharmaceuticals Wins FDA Approval of Sleep Disorder Drug
Wall St Cheat Sheet
Saturday, February 1, 2014 - 10:44am
tags:
Hetlioz, Vanda, sleep aid, hypnotics
Two biotech IPOs blast off, spurring dreams--and fears--of an attempted gold rush
Fierce Biotech
Friday, January 31, 2014 - 9:11am
tags:
IPOs, biotech, Dicerna Pharmaceuticals, Ultragenyx
Mylan Named as Gilead's Exclusive Branded Medicines Business Partner for India
Yahoo
Friday, January 31, 2014 - 9:08am
tags:
Mylan, generics, Gilead Sciences, India
Merck joins other drugmakers, contract research labs vowing not to do research on chimpanzees
Yahoo/AP
Friday, January 31, 2014 - 8:46am
tags:
Merck, R&D, animal research

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Cleaning Up the Medical Literature
In the Pipeline
Not One of Your Easy Crystals
In the Pipeline
The Continuing Crisis, Part XV: The Horrendous Trump Budget
In the Pipeline
Taurine Revisited
In the Pipeline
A New Route to Asthma Treatment - Through the Liver, of All Places
In the Pipeline
One Drug's Supply Chain, In Detail
In the Pipeline
A Reaction to Alzheimer's Fraud
In the Pipeline
Whoa Now: Cautionary Tales from Materials Science
In the Pipeline
Inside a Scientific Paper Mill
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.